{
    "symbol": "CERE",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-13 00:43:18",
    "content": " Although certain of our data readout time lines in this program are under review, all three of our Phase III trials in early and late-stage Parkinson's disease are ongoing, along with the corresponding open-label extension. Your line is open. Your line is open. So as you know, and I think Tony has mentioned that there has been a residual effect due to the COVID era, and you're seeing basically the effect at the site, at the trial site level, as well as at the CRO levels and other associated organizations and there's a bolus of trials that really are trying to catch up, but the personnel really can't catch up as quickly. Your line is open. Your line is open. Your line is open. Your line is open. Operator, we will take the next question. Your line is open. Operator, we will take the next question. Your line is open. So there's nothing unique in terms about the design or we're not doing anything differently because it's darigabat, but we do hope it's like we saw in the hypercapnia trial, that the Alpha 2/3 cell activity will obviously give us the opportunity to show the benefits of a chronic dosing of darigabat to be like a benzodiazepine without the Alpha-1 side effect issues and issues for chronic."
}